Resumen de SEOM guidelines for the management of Malignant Melanoma 2015

Alfonso Berrocal Jaime, Ana Arance Fernández, E. Espinosa Arranz, Almudena García Castaño, María González Cao, José Luis González Larriba, José Antonio López Martín, Iván Márquez Rodas, Ainara Soria, Salvador Martín Algarra

• All melanoma patients must be confirmed histologically and resected according to Breslow. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon must be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 therapy. Up to 10 years follow up is recommended for melanoma patients with dermatologic examinations and physical exams.